F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Moderna announced that the U.S. Food and Drug Administration (FDA) had reversed its previous decision and agreed to review the company's flu vaccine application during recent discussions in Washington, D.C., after additional regulatory dialogues between the biotech firm and federal health officials. Following initial rejection of their application, Moderna engaged in further discussions with FDA regulators to address concerns about the mRNA-based influenza vaccine. The biotechnology company, known for its COVID-19 vaccine developed with similar technology, expressed optimism that this regulatory breakthrough could pave the way for a new generation of flu vaccines with potentially greater efficacy and easier production methods compared to traditional vaccine manufacturing processes. The mRNA technology used in Moderna's flu vaccine works by instructing cells to produce proteins that trigger an immune response, similar to the mechanism used in their successful COVID-19 vaccine. If approved, this vaccine would represent a significant advancement in flu prevention, potentially offering better protection against seasonal influenza and reducing the need for annual reformulation of vaccines based on predicted virus strains.